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In demyelinating diseases including multiple sclerosis (MS), neural stem cells (NSCs) can
replace damaged oligodendrocytes if the local microenvironment supports the required dif-
ferentiation process. Although chitinase-like proteins (CLPs) form part of this micro-
environment, their function in this differentiation process is unknown. Here, we demonstrate
that murine Chitinase 3-like-3 (Chi3l3/Ym1), human Chi3L1 and Chit1 induce oligoden-
drogenesis. In mice, Chi3l3 is highly expressed in the subventricular zone, a stem cell niche of
the adult brain, and in inflammatory brain lesions during experimental autoimmune ence-
phalomyelitis (EAE). We find that silencing Chi3l3 increases severity of EAE. We present
evidence that in NSCs Chi3l3 activates the epidermal growth factor receptor (EGFR), thereby
inducing Pyk2-and Erk1/2- dependent expression of a pro-oligodendrogenic transcription
factor signature. Our results implicate CLP-EGFR-Pyk2-MEK-ERK as a key intrinsic pathway
controlling oligodendrogenesis.
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O ligodendrocytes constitute one of the four principalcentral nervous system (CNS) cell types—along withneurons, astrocytes, and microglia. Within the CNS,
oligodendrocytes form myelin sheaths around axons, a pre-
requisite for efficient signal conduction. However, oligoden-
drocytes are highly susceptible to injury owing to their elevated
metabolic rate and ATP requirement for the synthesis of myelin
membranes1. Thus, oligodendrogenesis, i.e., differentiation of
oligodendrocytes from neural stem cells (NSCs), is vital for both
the developing and the adult CNS, ensuring repair and replen-
ishment of damaged myelin.
In the adult brain, NSCs from the subventricular zone (SVZ), a
specialized adult stem cell niche adjacent to the lateral ventricle,
contribute to local myelin repair by differentiating into oligo-
dendrocyte precursor cells (OPCs) that migrate to the site of
injury and subsequently mature into myelinating oligoden-
drocytes2–7. Activation of endogenous NSCs is not cell-autono-
mous, but depends on the SVZ microenvironment3,8,9, which is
shaped by SVZ microglia and infiltrating macrophages by means
of cell-to-cell contact and/or soluble immune mediators10–13.
In demyelinating diseases, such as multiple sclerosis (MS) and
the animal model experimental autoimmune encephalomyelitis
(EAE), failure of oligodendrogenesis and remyelination result in
chronic demyelination and axon degeneration, causing severe
disabilities14–16. Thus, understanding the molecular mechanisms
that drive oligodendrogenesis is crucial for developing strategies
for remyelination.
It is known that the activation state of microglia determines
their niche-supporting function17,18. In EAE, activated microglia
have regeneration-supporting functions during the acute phase of
the disease and seem to be nonpermissive for oligodendrogenesis
and remyelination during chronic disease9,18.
The regeneration-supporting microglia express high levels of
chitinase 3-like-3 (Chi3l3, Ym1), a known marker for alternative
activation of microglia and macrophages (M2)19. Chi3l3 is a
member of a family of mammalian chitinase-like proteins (CLPs)
that share homology to chitinases of lower organisms but lack
enzymatic activity13,20. Chi3l3 has been implicated in immuno-
modulation21–23, but its function in the CNS is essentially
unknown.
Here, we show that Chi3l3 serves as an activator of the epi-
dermal growth factor receptor (EGFR) and induces fate choice
towards the oligodendroglial lineage in NSCs in vitro and in vivo.
This effect is accompanied by the upregulation of Olig1, Olig2,
Sox10, and downregulation of their negative transcriptional reg-
ulators Id2, Id4, and Hes5, and is mediated by induction of the
mitogen-activated protein kinase (MAPK) pathway in a Pyk2-
dependent fashion. Furthermore, our data point toward a critical
role of Chi3l3 in reducing disease severity at onset and during
chronic autoimmune demyelination.
Results
Dynamic regulation of endogenous Chi3l3 in the adult SVZ.
We measured Chi3l3 gene expression and protein levels in the
CNS during relapsing-remitting EAE using quantitative real-time
PCR (qRT-PCR) and immunostaining, respectively. Naive mice
expressed very modest levels of Chi3l3 in the SVZ (Fig. 1a).
During acute EAE, Chi3l3 gene expression increased to 78-fold
before onset of EAE, 298-fold during onset of clinical EAE signs
and to 3471-fold during peak disease. Chi3l3 gene expression
decreased again thereafter to a 35-fold expression during initial
recovery and to ninefold expression during chronic EAE, when
compared with healthy control mice (Fig. 1a). Chi3l3 protein
levels were analyzed during acute and chronic EAE. Immuno-
fluorescent signal was only detectable during acute EAE (Fig. 1b)
but not chronic EAE (Supplementary Figure 1A). In agreement
with previous reports19,24, Chi3l3 protein expression colocalized
with the microglia- and macrophage marker CD11b (Fig. 1b–d),
but not with CD4+-infiltrating T cells (Supplementary Figure 1
B–E). Chi3l3-expressing cells were located periventricularly
(Fig. 1c), and in lesions abutting the SVZ. (Fig. 1b, d). Chi3l3+
CD11b+ cells constituted a heterogeneous population that
expressed the activation marker CD45 at high (Fig. 1d, yellow
arrowhead) or low levels (Fig. 1d, white arrowhead) and displayed
either round (Fig. 1e upper panel) or ramified (Fig. 1e, lower
panel) morphology. These results indicate that CD11b+ myeloid
cells including resident microglia and infiltrating macrophages
upregulate Chi3l3 expression during the course of EAE pre-
dominantly during acute EAE.
Chi3l3 induces oligodendrogenesis in vitro. We investigated the
effects of Chi3l3 on NSCs in vitro, focusing on the differentiation
of NSCs into the three neural lineages as well as self-renewal
capacity, proliferation, and cell death. We found that NSCs that
differentiated in the presence of recombinant Chi3l3 for 3 days
(early precursors, Fig. 2a–d) or 5 days (mature cells, Fig. 2e–h)
had a higher proportion of NG2-expressing OPCs (Fig. 2a) and
O4+ oligodendrocytes (Fig. 2e) than control NSCs and a lower
proportion of glial fibrillary acidic protein (GFAP)-expressing
astrocytes (Fig. 2b, f), doublecortin (Dcx)+ neural precursors
(Fig. 2c) and Map2+ mature neurons (Fig. 2g). The relative
increase in Sox2+ stem cells detected on day 5 (Fig. 2h) was not
owing to proliferation of the stem cells, as levels of BrdU incor-
poration were below 1% for both vehicle and Chi3l3-stimulated
NSCs (Supplementary Figure 2A, B). Furthermore, we examined,
whether Chi3l3 also affected OPC maturation towards myeli-
nating oligodendrocytes. Exposure of primary OPCs to recom-
binant Chi3l3 for 7 days, positively affected the percentage of
MBP+mature oligodendrocytes compared with control (Fig. 2i).
The Chi3l3-mediated effects on NSC differentiation were dose-
dependent (Supplementary Figure 3). Chi3l3-mediated oligoden-
drogenesis was accompanied by a significant increase in Cspg4
(NG2) gene expression and a reduced expression of Map2 and
Gfap (Fig. 2j–l).
Chi3l3 did not significantly affect proliferation of NSCs, as
measured by Ccnd1 and Ccnd2 expression (Fig. 2m, n) and
Ki67 staining in total cells (Ki67+/DAPI), OPCs (Ki67+/NG2+
cells), and non-OPCs (Ki67+/NG2− cells) (Supplementary
Figure 2C). Chi3l3 also did not affect cell survival, as measured
by propidium iodide (PI) uptake (Supplementary Figure 2D), or
self-renewal capacity, as measured by neurosphere number and
size (Fig. 2o, p). Thus, Chi3l3 directs NSC fate choice toward
oligodendrogenesis without affecting proliferation, self-renewal
capacity, or cell survival.
It is widely accepted that alternatively activated microglia/
macrophages are key players in modulating NSC fate choice toward
oligodendrogenesis17, but the specific mechanisms are unknown.
To investigate the role of Chi3l3 in microglia-induced oligoden-
drogenesis, we knocked down Chi3l3 expression in BV-2 microglia
cells and performed medium-transfer assays with NSC cultures.
Silencing Chi3l3 in BV-2 microglial cells led to effective loss of
Chi3l3 protein (Supplementary Figure 4A, B) and indeed, prevented
microglia-induced oligodendrogenesis (Supplementary Figure 4C).
Taken together, the data show that Chi3l3 affects differentia-
tion of NSCs toward OPCs and mature oligodendrocytes.
Chi3l3 induces oligodendrogenesis through MAPK signaling.
We measured genetic regulators of oligodendrogenesis in Chi3l3-
treated NSCs by quantitative RT-PCR. Genes encoding crucial
pro-oligodendrogenic differentiation factors, such as Olig1, Olig2,
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and Sox10, were significantly upregulated in Chi3l3-treated NSCs
compared with control NSCs (Fig. 3a), whereas negative reg-
ulators of oligodendrogenesis including Id2, Id4, and Hes5, were
significantly downregulated (Fig. 3b).
Using reverse-phase protein arrays, we identified the kinetics
(0–30min) of phosphorylation-patterns of a spectrum of signaling
nodes involved in NSC fate choice and inflammation, indicating
activation of these kinases25–27. Chi3l3 significantly increased the
phosphorylation of proteins in the MAPK/phospho-inositol-3-
kinase (PI3K) pathways including Pyk2 (Tyr402), PLCγ2 (Tyr1217),
cRaf (Ser259), PI(3)K p85 (Tyr458), p38MAPK (Thr180/Tyr182) and
Erk1,2 (Thr202/Tyr204) (Supplementary Figure 5).
This phosphorylation pattern was confirmed at the single-cell
level by fluorescence microscopy (Fig. 3c). A significant increase
in phosphorylation of Pyk2 (Tyr402), cRaf (Ser259) and p38MAPK
(Thr180/Tyr182) was detected as early as 5 min post exposure to
Chi3l3, followed by phosphorylation of PLCγ2 (Tyr1217), PI(3)K
p85 (Tyr458) and Erk1,2 (Thr202/Tyr204) at 15 min post exposure.
Activation of p38MAPK (Thr180/Tyr182), occurred only transi-
ently, but phosphorylation of all other kinases analyzed was
sustained for 30 min (Fig. 3c).
To link signaling molecules with transcriptional regulators
modulated by Chi3l3, we performed bioinformatic pathway analysis
using Ingenuity® pathway analysis (IPA). The latter revealed that
Pyk2 (Ptk2b) was predicted to be upstream in the MAPK pathway,
whereas Erk1/2 was predicted to be the central signaling node
connecting the MAPK pathway with the network of transcriptional
regulators via the induction of Olig2 expression (Fig. 3d).
To test these predictions we used the potent Pyk2 inhibitor PF-
43139628 and the MEK-ERK inhibitor U0126 and measured Olig2
expression. Exposure of NSCs to Chi3l3 in the presence
of PF-431396 or U0126 resulted in significant inhibition of
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Fig. 1 Endogenous Chi3l3 expression in the adult SVZ during EAE. a Chi3l3 gene expression in the subventricular zone (SVZ) of healthy control mice (HC;
n= 8), preclinical EAE (6 days post immunization (dpi; n= 6), EAE onset (13dpi; n= 6), acute EAE (14 dpi; n= 6), initial recovery (18 dpi; n= 8) and
chronic EAE (36 dpi, n= 6) measured by qRT-PCR (multiple t -tests with Dunn–Bonferroni’s multiple comparison test). b–e Confocal images of the SVZ of
representative healthy controls (HC), acute EAE mice (12–14 dpi). Sections were immunostained for the nuclear marker TO-PRO-3 (blue), Chi3l3 (red) and
the microglia/macrophage marker CD11b (green, b–e) and the lymphocyte common antigen CD45 (blue, d). Chi3l3 expression in the SVZ was only
detected during acute EAE and was localized to CD11b-positive cells (yellow arrowheads) within the corpus callosum (CC) c and lesions d, where they co-
expressed CD45 at high (yellow arrowhead) and low levels (white arrowhead). Dashed lines mark the wall of the lateral ventricle (LV). Scale bar, 200 μm.
e Ortho-view images of representative Chi3l3+/CD11b+ double-positive cells exhibiting round (upper panel) and ramified (lower panel) morphology.
(mean ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.005)
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Chi3l3-induced Olig2 expression (Fig. 3e, g). In line with our
results from pharmacological inhibition, knockdown of Ptk2b
(Supplementary Figure 6A) and overexpression of dominant-
negative Erk2-K54R (Supplementary Figure 6B) resulted in
significantly decreased Chi3l3-induced Olig2 expression (Fig. 3f,
h). Furthermore, both, pharmacological inhibition of
Pyk2 signaling and knockdown of Ptk2b expression in NSCs,
resulted in significant reduction of Chi3l3-induced oligodendro-
genesis (Fig. 3i, j), linking the Chi3l3-dependent activation of the
MAPK pathway with its downstream transcriptional targets and
function in oligodendrogenesis.
Chi3l3 activates EGFR to promote oligodendrogenesis. To
predict the membrane-bound activators through which Chi3l3
induced the MAPK pathway, we performed an upstream-analysis
using IPA. The method identified five membrane-bound kinases
that are upstream of the signaling modules activated by Chi3l3
and that could serve as potential receptors (Fig. 4a). Among the
identified upstream molecules was the receptor tyrosine kinase
EGFR, also known as ErbB1 or HER-1.
EGFR can homodimerize or heterodimerize with other ErbB
family members upon binding of peptide ligands, triggering
tyrosine phosphorylation and activation of downstream signaling
cascades. EGFR regulates a broad spectrum of cellular functions
including oligodendrogenesis and remyelination29–31. We inves-
tigated the phosphorylation status of EGFR in differentiating
NSCs, and found that Chi3l3 and its canonical ligand EGF
significantly induced phosphorylation of the EGFR at tyrosine
1068 after 15 min (Fig. 4b). Next, we tested whether pharmaco-
logical inhibition of EGFR signaling affected Chi3l3-mediated
oligodendrogenesis in vitro. Here we used the pharmacological
inhibitors AZD8931/Sapatinib and Gefitinib, blocking the
complete EGFR family and EGFR, respectively. Both AZD8931
and Gefitinib resulted in inhibition of Chi3l3-induced oligoden-
drogenesis (Fig. 4c). Similarly, knockdown of EGFR expression in
NSCs (Supplementary Figure 6C) significantly reduced Chi3l3-
mediated oligodendrogenesis (Fig. 4d). Furthermore, inhibition of
EGFR signaling by pharmacological inhibition or knockdown
resulted in inhibition of Chi3l3- and EGF-dependent Pyk2
phosphorylation (Fig. 4e, f), indicating that Pyk2 is a downstream
target of EGFR activity during Chi3l3-dependent NSC activation.
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Fig. 2 Chi3l3 directly promotes oligodendrogenesis in vitro. Representative confocal image (above) and quantification (below) of neural stem cells (NSCs)
cultured in the presence of PBS (control) or Chi3l3 (100 ng/ml) for 3 days a–d, 5 days e–h, or primary OPCs cultured in the presence of PBS (control) or
Chi3l3 (500 ng/ml) for 7 days i. Cells were treated with the nuclear stain TO-PRO-3 (blue) and immunostained for early progenitor markers NG2
(a; oligodendrocyte precursor cells, green), GFAP (b; astrocytes, green), Dcx (c; neuroblasts, green), late progenitor markers O4 (e; oligodendrocytes,
green), GFAP (f; astrocytes, green) and microtubule-associated protein 2 (g; Map2, neurons, green), the neural stem cell marker Sox2 (d, h; green) and the
myelin protein MBP (i, oligodendrocytes, green). Exposure of differentiating NSCs to Chi3l3 led to significant increase in oligodendrocyte precursor cells
and oligodendrocytes, significant decrease in astrocytes, neuroblasts, and neurons and a significant increase in Sox2+ neural stem cells. Scale bar, 50 μm.
Inserts show representative cells. Scale bar, 20 μm. j–n Gene expression of Cspg4 (NG2; j), Gfap k, and Map2 (l; 3 days) and Ccnd1 and Ccnd2 (m, n; 24 h)
mRNA in PBS (control) or Chi3l3-treated differentiating NSCs. Values were normalized against Gapdh (AU, arbitrary unit; n.s., not significant;). Number
o and size p of neurospheres from NSCs exposed to Chi3l3 or PBS (control). (n.s., not significant; two-tailed Student’s t test; data are representative of
three independent experiments with n= 5 replicates a, c, d, i, n= 9 (Control) and 10 (Chi3l3) replicates b, n= 12 (Control) and 9 (Chi3l3) replicates e, n=
12 replicates f, g, n= 3 replicates h, j, l, m, n), n= 3 (Control) and 2 (Chi3l3) replicates k, n= 4 replicates o, n= 8 (control) and four (Chi3l3) replicates p).
mean ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.005
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These data indicate that Chi3l3 induces oligodendrogenesis by
activating Pyk2 in an EGFR-dependent manner.
Chi3l3 infusion induces oligodendrogenesis in vivo. To test
whether Chi3l3 affects NSC fate choice in vivo, we pulsed naive
mice with 5-bromo-2’deoxyuridine (BrdU) for 6 days to label
SVZ-NSCs and then followed differentiation into their cell fates
after stereotactical injection of recombinant Chi3l3 (500 ng/
mouse) or vehicle into the right lateral ventricle (RLV) (Fig. 5a).
The percentage of NSCs that differentiated into OPCs was
quantified for the ipsilateral (IL) and contralateral (CL) SVZ of
Chi3l3 and vehicle-infused mice18,32–34. The IL SVZ of Chi3l3-
injected mice was compared with the IL SVZ of vehicle-treated
mice as well as the CL SVZ of the same mouse. We found that the
percentage of newly formed NG2+ BrdU+ OPCs was significantly
increased (Fig. 5b, c), whereas the percentage of NSC-derived Dcx
+ BrdU+ neuroblasts was significantly decreased (Fig. 5d, e) in
the ipsilateral but not contralateral SVZ when compared with
vehicle-infused mice. The overall number of BrdU+ cells in the
ipsilateral and contralateral SVZ of Chi3l3- and vehicle-treated
mice was not significantly altered (Fig. 5f). We confirmed that
Chi3l3 had no effect on NSC proliferation in vivo by injecting
recombinant Chi3l3 (500 ng/mouse) or vehicle into the RLV of
mice. Proliferating NSCs were labeled by pulsing mice with BrdU
12 and 24 h after Chi3l3 infusion. Mice were killed 24 h after the
last pulse and the number of BrdU-incorporating cells in the SVZ
of both groups were quantified. In line with our results in vitro,
Chi3l3 did not significantly affect proliferation of SVZ cells
in vivo (Supplementary Figure 7).
Thus, infusion of Chi3l3 into the SVZ of naive mice induces
fate choice of NSCs towards OPCs at the expense of neuroblasts
and without affecting NSC proliferation in vivo.
Chi3l3 affects oligodendrogenesis and severity of EAE. To
investigate the role of SVZ-derived Chi3l3 during autoimmune
demyelination, we used lentivirus-delivered small hairpin RNAs
(shRNA LVPs) to silence Chi3l3 expression inside the SVZ prior
to induction of relapsing-remitting EAE (Chi3l3-sh mice, control-
sh mice). Mice were pulsed with BrdU on days 3–6 after
immunization and then killed at disease onset, or on day 32 when
they had entered the chronic EAE phase. Histopathological
analysis was performed on CNS tissue to assess the degree of
oligodendrogenesis, myelination, and lesion load (Fig. 6a).
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Fig. 3 Chi3l3 induces a pro-oligodendrogenic transcriptional and signaling profile. a, b Gene expression of the pro-oligodendroglial transcription factors
Olig1, Olig2, and Sox10 after 36 h a and negative transcriptional regulators Id2, Id4, and Hes5 after 24 h b in differentiating neural stem cells (NSCs) post
exposure to Chi3l3 or PBS (control). cMean fluorescence intensity (MFI) quantification of individual NSCs, activated by Chi3l3 or PBS (control), fixed at 5,
15, and 30min and immunostaining for phosphorylation (p)- specific antibodies to various signaling proteins. d Ingenuity pathway analysis showing
interconnection between Chi3l3-mediated signaling events (Ptk2b (Pyk2), MAPK14 (p38MAPK), PLCG2 (PLCγ2), RAF1 (c-Raf), ERK1/2, PI3K p85 and
transcriptional events (Olig1, Olig2, Sox10, Hes5, Id2, Id4). e, f Gene expression of Olig2 in differentiating NSCs in the presence of Pyk2 kinase inhibitor PF-
431396 e or NSCs, transfected with control shLVPs or Ptk2b (Pyk2) shLVPs f after 36 h of exposure to Chi3l3 or PBS. g, h Gene expression of Olig2 in
differentiating NSCs in presence of MEK-Erk inhibitor U0126 g or NSCs, transfected with LVPs containing GFP (control) or dnErk2-GFP h after 36 h of
exposure to Chi3l3 or PBS. Values were normalized to housekeeping genes and expressed as percent change to PBS-treated control NSCs. i Quantification
of NG2+ oligodendrocyte precursor cells, derived from NSCs differentiated for 3 days in the presence (+ ) or absence (−) of PF-431396 and Chi3l3 (+ )
or PBS (−). j Quantification of NG2+ oligodendrocyte precursor cells derived from differentiating NSCs, transfected with control shLVPs or Ptk2b shLVPs
(Pyk2), and treated with Chi3l3 (+ ) or PBS (−). Pyk2 signaling deficiency significantly reduced Chi3l3-induced oligodendrogenesis. Values are expressed
as percent change to the corresponding PBS-treated group. Two-tailed Student’s t test was performed for a–c, one-way ANOVA followed by Turkey’s post
hoc test was performed for e–j; Data are representative of three independent experiments. For n numbers please refer the Methods section; mean ± s.e.m.
*p < 0.05; **p < 0.01; ***p < 0.005
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Control-sh mice developed acute disease peaking at 12–14 dpi
followed by initial recovery, relapse, and subsequent remission at
dpi 26, as expected in this model12,18. In contrast, Chi3l3-sh mice
developed EAE earlier than control mice, followed by a similar
disease course during the acute EAE phase, but significantly
increased disease severity during the chronic phase (Fig. 6b).
During disease onset, the percentage and absolute numbers of
newly formed NG2+BrdU+ OPCs as well as newly formed CC1
+BrdU+ mature oligodendrocytes in the ipsilateral periventri-
cular area were significantly decreased in Chi3l3-sh mice
compared with control-sh mice (Fig. 6c). During chronic EAE
Chi3l3-sh mice showed decreased numbers of NG2+ cells in the
periventricular area (Fig. 6d), whereas the number of newly
formed CC1+ BrdU+ mature oligodendrocytes and Luxol Fast
Blue myelin staining (Supplementary Figure 8) was unchanged.
The number of inflammatory lesions was not significantly
altered in sections of brain and spinal cord tissue at onset or
chronic disease (Fig. 6e, f). Furthermore, we did not observe
activation of the central (Supplementary Figure 9A, Supplemen-
tary Figure 10A) or peripheral immune system (Supplementary
Figure 9B, Supplementary Figure 10B). Thus, the observed
decrease in OPC generation in Chi3l3-sh mice is consistent with
a mechanism of Chi3l3-induced clinical recovery that involves
oligodendrogenesis, but not alterations of the immune system.
Human CHIT1 and CHI3L1 induce oligodendrogenesis
in vitro. To examine the potential clinical relevance of our
findings, we analyzed the effects of the human paralogues,
CHI3L1 and CHIT1, on differentiation of human NSCs in vitro.
Like murine Chi3l3, both human paralogues significantly induced
differentiation of human NSCs into NG2+ OPCs and MBP+
mature oligodendrocytes (Fig. 7a, b, e) and reduced astrogliosis
(Fig. 7b, e). The percentage of DCX+ and SOX2+ cells was
unchanged (Fig. 7a, d, e). These results show that human para-
logues to murine Chi3l3 are also capable of inducing
oligodendrogenesis.
Discussion
Our data suggest that the dynamics of Chi3l3 expression
controls oligodendrogenesis and affects disease severity
throughout the course of autoimmune demyelinating disease.
Mechanistically, our results provide evidence that Chi3l3, a
mammalian lectin previously known only as a marker for M2
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Fig. 4 Chi3l3 promotes oligodendrogenesis by inducing EGFR signaling. a ingenuity pathway analysis showing membrane-bound receptors (EGFR, FGFR1,
DLG4 (PSD95), NTRK2, FYN) upstream of Chi3l3-induced MAPK signaling (Ptk2b (Pyk2), MAPK14 (p38MAPK), PLCG2 (PLCγ2), RAF1 (c-Raf), ERK1/2,
PI3K p85) and pro-oligodendrogenic transcriptional pattern (Olig1, Olig2, Sox10, Hes5, Id2, Id4). b Mean fluorescence intensity (MFI) quantification of
individual neural stem cells (NSCs), activated by Chi3l3, EGF, or PBS (control) for 15 min, and immunostaining for phospho (p)-specific EGFR (Tyr1068).
One-way-ANOVA with Dunn’s multiple comparison test; c Quantification of NSC-derived NG2+ oligodendrocyte precursor cells after 3 days of
differentiation in the presence of Chi3l3 (+ ) or PBS (−) and EGFR kinase inhibitor AZD8931 (+ , left) and Gefitinib (+ , right) or DMSO (−). One-way
ANOVA with Bonferroni’s multiple comparison test; d Quantification of NG2+ oligodendrocyte precursor cells derived from differentiating NSCs,
transfected with control shLVPs or EGFR shLVPs and treated with Chi3l3 (+ ) or PBS (−). Deficiency in EGFR signaling significantly reduced Chi3l3-
induced oligodendrogenesis. One-way ANOVA with Bonferroni’s multiple comparison test; e Mean fluorescence intensity (MFI) quantification of NSCs,
activated by Chi3l3 (+ ), EGF (+ , positive control) or PBS (−, negative control) in the presence of EGFR inhibitor AZD8931 for 15 min, and
immunostaining for phospho (p)-specific Pyk2 (Tyr402). One-way ANOVA with Bonferroni’s (d, neuroblasts, red) test; f Mean fluorescence intensity
(MFI) quantification of NSCs transfected with control shLVPs or EGFR shLVPs, activated by Chi3l3 (+ ), EGF (+ , positive control) or PBS (−, negative
control for 15 min, and immunostained for phospho (p)-specific Pyk2 (Tyr402). Deficiency in EGFR signaling reduced Pyk2 phosphorylation in neural stem
cells. All values are expressed as percent change to PBS-treated NSCs. One-way ANOVA with Bonferroni’s multiple comparison test; mean ± s.e.m; *p <
0.05; **p < 0.01; ***p < 0.005
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microglia/macrophages, is an activator of EGFR and induces
oligodendrogenesis by activating MAPK signaling and pro-
oligodendrogenic transcriptional regulation in a Pyk2-
dependent manner (for the presumptive mechanistic pathway,
see Fig. 8).
The regulation of NSC fate choice largely depends on the SVZ
microenvironment3,8,9, which is significantly shaped by soluble
mediators present in the cerebrospinal fluid (CSF)35 or produced
by local microglia36. Both local microglia and the CSF composi-
tion undergo dynamic changes in response to different
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Fig. 6 Subventricular zone-derived Chi3l3 affects EAE severity and oligodendrogenesis. a Protocol of shRNA lentiviral particle (LVP) administration, BrdU
injection, and EAE induction. b Clinical score (left) and linear regression curves (right) of mice treated with control shRNA LVPs (black line) or
Chi3l3 shRNA LVPs (red line) and immunized with PLP139–151. Dashed lines indicate 95% confidence intervals. (n= 23 control shRNA LVP and 27
Chi3l3 shRNA LVP mice per group; two-way ANOVA; c Quantifications of percentage (left) and number (right) of NG2+/BrdU+ double-positive cells in
the ipsilateral (IL) and contralateral (CL) SVZ of Chi3l3 shLVP and control shLVP mice killed at onset of disease in vivo. (n= 4 per group; two-tailed
Student’s t test; d Quantifications of and number of NG2+ cells in the ipsilateral (IL) and contralateral (CL) SVZ of Chi3l3 shLVP and control shLVP mice
sacrificed during chronic EAE (n= 8 control shRNA mice, n= 6 Chi3l3 shRNA mice; two-tailed Student’s t test. e, f Localization (left) and quantification of
inflammatory lesions in brain sections (middle) and spinal cord sections (right) of Chi3l3 shLVP and control shLVP mice killed at EAE onset (e; n= 4 mice
control shRNA, n= 5 mice Chi3l3 shRNA (left, brain), n= 5 mice per group (right, spinal cord; two-tailed Student’s t-test; mean ± s.e.m) and during chronic
EAE (f, n= 7 mice control shRNA mice, n= 8 Chi3l3 shRNA mice (left, brain) and n= 8 mice control shRNA mice, n= 6 Chi3l3 shRNA mice (right, spinal
cord); two-tailed Student’s t test). Schematic diagram showing localization of inflammatory lesions of individual mice, each color represents an individual
mouse. (mean ± s.e.m.; *p < 0.05; **p < 0.01; ***p < 0.005)
Fig. 5 Chi3l3 infusion induces pro-oligodendrogenic fate of subventricular zone neural stem cells in vivo. a Protocol of BrdU labeling via intraperitoneal (i.p.)
injection and Chi3l3 administration. b–f Representative confocal images b, d and quantification c, e, f of the ipsilateral (IL) or contralateral (CL)
subventricular zone (SVZ) of naive mice infused with Chi3l3 or PBS (vehicle) and immunostained for BrdU (green) and NG2 (b, oligodendrocyte precursor
cells, red) or Dcx (d, neuroblasts, red). IL SVZ of Chi3l3-treated mice were compared with IL SVZ of vehicle-treated mice as well as the CL site of the same
mouse. Dashed lines mark the ventricular wall of the right or left lateral ventricle (RLV; LLV). Scale bar (left), 50 μm. Double-positive cells are indicated by
yellow and white arrowheads and representative cells (box) are shown as high magnification images (right). Scale bar (right), 5 μm. Quantifications show a
significantly higher percentage of BrdU/NG2 double-positive cells c and reduced percentage of BrdU+/Dcx+ cells e in the ipsilateral SVZ of Chi3l3 infused
mice indicating pro-oligodendrogenic modulation of SVZ stem cell fate choice in vivo. f Quantification of the total number of BrdU labeled cells/mm2 in the
SVZ showed no significant difference between Chi3l3 or vehicle infusion in the ipsilateral or contralateral SVZ. (One-way ANOVA with Turkey’s post hoc
test; c n= 2 mice (Control IL, CL), n= 4 (Chi3l3 IL), and n= 3 (chi3l3 CL); e n= 2 mice per group, n= 4 mice per group; mean ± s.e.m. *p < 0.05; **p <
0.01; ***p < 0.005)
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08140-7
8 NATURE COMMUNICATIONS |          (2019) 10:217 | https://doi.org/10.1038/s41467-018-08140-7 | www.nature.com/naturecommunications
physiological and pathophysiological states37. However, little is
known about how these changes in the local microenvironment
affect neural stem cell behavior. Here, we show that endogenous
Chi3l3 is expressed by CD11b+ myeloid cells in the SVZ and its
expression parallels the dynamic regulation of oligodendrogenesis
during the course of autoimmune demyelinating disease38,
reaching its highest expression at peak disease and decreasing
thereafter.
Our work shows that infusion of Chi3l3 into the CSF of healthy
mice with low Chi3l3 expression resulted in a modulation of NSC
fate choice toward the oligodendrocyte lineage without affecting
proliferation in vivo. In line with these results, and strongly
supporting a role for Chi3l3 as an essential regulator of oligo-
dendrogenesis in vivo, local suppression of EAE-induced Chi3l3
expression in the SVZ led to decreased oligodendrogenesis. It is
likely that shRNA LVPs integrated into microglia lining the
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ventricular wall, in line with earlier studies using a similar
experimental design39,40. These presumptive target cells are
known to highly express Chi3l3. However, further studies are
needed to provide direct evidence for the exact localizations of
virus infection and therefore, of Chi3l3 knockdown.
In accordance to our in vitro data, suppression of Chi3l3
expression blocked differentiation of NSCs into OPCs and further
into mature oligodendrocytes during onset of clinical signs in
EAE mice. However, the fact that the OPC differentiation as well
as differences in normal myelin staining were not observed
during chronic EAE may indicate that OPC differentiation and
remyelination are either overcome or inhibited by other factors of
the chronic microenvironment. We must bear in mind that
although the in vitro data strongly support the notion that Chi3l3
acts directly on NSC, our in vivo data do not exclude potential
indirect effects of the Chi3l3 on oligodendrogenesis. EGFR is
expressed on choroid plexus epithelial cells, ependymal cells and
type-C cells of the SVZ41. Thus, in the in vivo context, Chi3l3
may also act by targeting those cells that are directly in contact
with the protein.
Chi3l3 knockdown increased EAE disease severity during the
onset and chronic phase of the disease without altering activation
of the peripheral and central immune system. However, a sur-
prising finding was that local knockdown of endogenous Chi3l3
in the SVZ did not affect severity or duration of the acute phase,
although Chi3l3 expression was maximal during acute EAE. A
potential explanation is that Chi3l3 is also expressed by periph-
eral monocytes and macrophages42. Thus, a local decrease of
Chi3l3 expression could potentially be compensated by the influx
of Chi3l3-expressing peripheral monocytes during acute EAE. As
these cells die rapidly43, the local decrease of Chi3l3 may re-
emerge during chronic EAE and may then result in alterations in
the clinical score. In addition, the clinical consequences of Chi3l3-
induced oligodendrogenesis could be either contemporaneous, or
results from knockdown in an earlier disease phase. It is a lim-
itation of the present study that we cannot distinguish all cell-
specific and disease phase-specific effects of Chi3l3 expression in
the CNS. Further limitations include the fact that although in this
model, clinical severity correlates with the magnitude of brain
lesions44, the EAE score largely reflects inflammation and tissue
damage in the lumbar spinal cord. Thus, further studies investi-
gating Chi3l3-mediated changes in the spinal cord of EAE mice
are ongoing to fully explain the causality between Chi3l3-
mediated effects and the EAE clinical score. In addition, the
cuprizone model of toxic demyelination will be useful to test
specific mechanistic aspects of Chi3l3-mediated oligoden-
drogenesis in the periventricular area and the corpus callosum. It
hast to be mentioned, that microglial Chi3l3 expression highly
increases during EAE but remains unchanged during the course
of cuprizone-mediated demyelination and subsequent remyeli-
nation45 pointing towards the importance of the autoimmune
activation cascade in initiating the Chi3l3-mediated repair
processes.
Our in vitro data show that Chi3l3 induces oligodendrogenesis
by directly targeting pro-oligodendrogenic NSC differentiation
without affecting proliferation, self-renewal capacity or cell death.
This effect was promoted by activating pro-oligodendrogenic and
pro-myelination transcription factors such as Olig1, Olig2, and
Sox10 and by diminishing expression levels of negative regulators
of oligodendrogenesis such as Id2, Id4 and Hes5. Chi3l3-mediated
pro-oligodendrogenic fate choice by activating the MAPK path-
way of cell growth and differentiation by means of phosphor-
ylation of signaling nodes including Pyk2 (Tyr402) and Erk1/2
(Thr202/Tyr204).
Pyk2 is a tyrosine kinase of the MAPK pathway46 and a sig-
naling molecule with known functions in tissue regeneration and
cancer28,47, however its function in NSCs had been unknown to
date. Strikingly, our phosphor-protein measurements and inhi-
bition studies demonstrate that Pyk2 signaling is required for
Chi3l3-induced Olig2 expression and abrogated Chi3l3-
dependent oligodendrogenesis suggesting that Pyk2 has an
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Fig. 8 Proposed model of Chi3l3-induced oligodendrogenesis. In the central
nervous system, Chi3l3 is expressed and secreted by alternatively activated
myeloid cells (MC), including resident microglia and infiltrating
macrophages. These cells are located in the corpus callosum (CC) and in
close proximity to the subventricular zone (SVZ) of the lateral ventricle
(LV). Chi3l3 binds to epidermal growth factor receptor (EGFR) on the
surface of endogenous neural stem cells (NSCs) and activates MEK/ERK
signaling and a pro-oligodendrogenic transcription factor pattern in a Pyk2-
dependent manner, leading to oligodendrogenesis
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important role in Chi3l3-induced modulation of NSC fate choice.
Whether Pyk2 signaling is also central to NSC functions induced
by stimulants other than Chi3l3 has to be elucidated.
Apart from differentiation, activation of the endogenous NSC
compartment also leads to proliferation, migration, and survival
of NSCs. Signaling by the EGFR, which is expressed on the cell
membrane of developing and adult NSCs, regulates all of these
effects29,48. Several different ligands of EGFR including EGF,
heparin-binding EGF-like growth factor (HB-EGF) and TGFα48,
have been identified, each controlling a specific function by sig-
naling via a particular downstream pathway. HB-EGF and TGFα
are associated with proliferation and survival of progenitors49. In
contrast, activation of EGFR signaling by EGF induces oligo-
dendrogenesis50 and was thought to be a promising agent to
enhance white matter repair. Counterintuitively, antibody-
mediated blockade of EGF in vivo was shown to ameliorate
EAE and induce oligodendrogenesis51. Furthermore treatment
with EGF induced substantial proliferation and migration of
progenitors, which led to diffuse hyperplasia of glial progenitors
in the white matter without differentiation into mature
oligodendrocytes50,52.
Our data suggest that Chi3l3, acting as a regulator of EGFR,
may have a better therapeutic potential, because it induces oli-
godendrogenesis without affecting proliferation, survival, and
self-renewal. Our phospho-protein analysis revealed EGFR as an
essential activator for Chi3l3-mediated oligodendrogenesis in
NSCs, and links Chi3l3-mediated EGFR activation with the
induction of main MAPK and PI3K signal transducers such as
Erk1/2 and p85-PI3K. Our data showed that Chi3l3 leads to
EGFR phosphorylation at Tyr1068, a site that is particularly
important for the induction of the Ras/MAPK pathway by
EGFR48. Importantly, blockade of EGFR activation by specific
inhibitors and knockdown of EGFR in NSCs abrogated Pyk2
phosphorylation, which was the earliest event detected in our
reverse-phase protein array kinetic experiment. We conclude that
EGFR activation is an immediate and essential event triggered by
Chi3l3, making Chi3l3 a compelling candidate as an EGFR ligand
or co-ligand.
The extracellular domain of EGFR is heavily N-glycosylated
and the glycosylation pattern is implicated in receptor dimer-
ization and subsequent activation53,54. Interestingly, the crystal
structure of Chi3l3 revealed a saccharide-binding site55 and
functional studies showed that Chi3l3 exhibited binding specifi-
city to saccharides with free amine groups, including glucosamine
(GlcN) and GlcN-polymers56, making it compatible with binding
to EGFR. However, further research is needed to elucidate whe-
ther Chi3l3 acts as a direct ligand to EGFR or activates it indir-
ectly. Taken together, our data provide evidence that the Chi3l3-
EGFR-Pyk2 axis constitutes a hitherto unknown pathway that
may be activated to induce pro-oligodendrogenic fate choice
without the induction of stem cell proliferation.
The family of mammalian CLPs also includes the structurally
and functionally related paralogues: murine Chi3l1 and human
CHI3L1 and CHIT1. Chi3l1 knockout mice have a more severe
course of MOG-induced EAE with increased demyelination36,
suggesting that several members of this protein family of CLPs
may have regenerative functions.
Similar to murine Chi3l3 and Chi3l1, their human paralogues
CHI3L1 and CHIT1 are highly abundant in the CNS during acute
demyelinating diseases, including relapsing-remitting MS
(RRMS) and neuromyelitis optica, but not chronic MS37. In
particular, CHI3L1 levels in the CSF were found to be sig-
nificantly higher in active progressive MS compared with inactive
progressive MS57,58, correlating with clinical and radiological
disease activity in RRMS patients38,58, and predicting conversion
from clinically isolated syndrome to MS59. CHI3L1 protein levels
in the CSF strongly correlated with markers of CNS tissue
damage and tissue remodeling including osteopontin, NFL, and
the myelin protein MBP41, whereas CHIT1 expression only
correlated with CSF levels of MBP42. Although CHI3L1 and
CHIT1 have been widely studied as biomarkers of disease pro-
gression and tissue damage in MS, their function in the CNS is
not yet clear. We now show that, like murine Chi3l3, human
CHI3L1 and CHIT1 induce oligodendrogenesis in human NSCs
in vitro. Notably, this may suggest that the in vivo expression of
CLPs, particularly during active MS participate in the disease
process as an attempt to initiate repair. This intriguing association
will spark new research into the biological role of these known
biomarkers.
However, embryonic mouse and human NSCs differ from each
other as well as from their adult counterparts60–62. This may
constitute a potential limitation, as embryonic NSCs expresses a
distinct set of biomarkers60 and are more plastic63 than adult
NSCs. Thus, future studies are needed to prove that CLPs induces
oligodendrogenesis by the above-described mechanism in mice
in vivo and caution has to be exercised when translating the
mechanistic findings of this study in a human and particularly
into a disease setting. Although direct evidence for the functional
role of human CLPs in the demyelinated CNS in vivo is still
lacking, human CHI3L1 and CHIT1 may also participate in pro-
oligodendrogenic fate choice during MS.
In summary, we have identified a hitherto unknown CNS
regulatory circuit by which microglia activate oligodendrogenesis
in endogenous NSCs through CLP-dependent mechanisms.
Chi3l3-induced stimulation of oligodendrogenesis was mediated
by induction of pro-oligodendrogenic transcription factors
downstream of EGFR-Pyk2-modulated MAPK-signaling path-
ways and correlated with amelioration of neurological symptoms
in vivo. Thus, targeting the Chi3l3-EGFR-Pyk2 signaling axis may
represent a therapeutic strategy to influence fate choice in NSCs
and promote oligodendrocyte repair in CNS diseases involving
white matter injury.
Methods
Animals. Female SJL/J/6 mice were purchased from the Jackson Laboratory (Bar
Harbor, ME, USA). All animals were housed in pathogen-free facilities. All
experiments were performed with the approval of the local animal welfare com-
mittees (Harvard Medical Area Standing Committee on Animals, and LAGeSo,
Berlin) and in accordance with national and international guidelines to minimize
discomfort to animals (NIH and 86/609/EEC).
Cell lines. 293 T cells were purchased from Life Technologies. These cells were
authenticated by Life Technologies. H9 hESC-derived NSCs (H9, N7800–100) were
purchased from Thermofisher scientific. These cells were authenticated by the
vendor and additional human genome sequencing and microarray analysis was
performed (data not shown). BV-2 cells were acquired as a kind gift from F. Aloisi
(Instituto Superiore di Sanità, 00161 Rome, Italy. These cells were positively tested
for microglial markers, however no further authentication was performed. Testing
for mycoplasma contamination was not performed.
Generation of lentiviral particles. Chi3l3 Mission® shRNA plasmid DNA in a
pLKO.1 vector backbone (clone ID: NM_009892.1–567s1c1), Ptk2b Mission®
shRNA plasmid DNA in a pLKO.1 vector backbone (clone ID: TRCN0000023632),
EGFR Mission® shRNA plasmid DNA in a pLKO.1 vector backbone (clone ID:
SHCLNG-NM_207655), and pLKO.1-puro control DNA were purchased from
Sigma. A dominant-negative Erk264 (dnErk2_K54R) was cloned into a lentiviral
gateway (Invitrogen) destination vector that contains the sequence of GFP in the
N-terminal position. The resulting expression plasmid contains a fusion of
dnErk2_K54R and GFP. The same expression plasmid backbone was used for the
control, from which only GFP is expressed. Cells expressing GFP- dnErk2_K54R in
addition to endogenous Erk1/2, show reduced phosphorylation of Erk1/2 targets
(data not shown). Lentiviral particles pseudotyped by the vesicular stomatitis viral
envelope were generated by transfecting 293 T cells (Life Technologies). Super-
natants were collected after 48 h, filtered through a 0.45 μm polyvinylidene
difluoride filter and concentrated overnight. The viral titer was determined
according to the manufacturer’s instructions, and stored at −80 °C.
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Stereotactic injection of Chi3l3 or lentiviral particles. Recipient mice
(5–7 weeks old) were anesthetized with ketamine (200 mg per kg) and xylazine (10
mg per kg). Heads were secured in a stereotaxic head frame (Stoelting). A small
hole was drilled into the mouse skull, meninges were locally removed with H2O2,
and a 10 μl Hamilton syringe with a 29 G needle was inserted into the right lateral
ventricle. Recombinant Chi3l3 (100 ng in 5 μl phosphate-buffered saline; PBS, RnD
Systems) or PBS (5 μl) or lentiviral particles (1 × 107 IU; shChi3l3 or shControl
(nontargeting) virus) were injected at a flow rate of 1 μl per min at the following
coordinates: anteroposterior, 0.34 mm; lateral, 1.2 mm; and dorsoventral, 2.4 mm.
After completion of injection, the needle was left in place for an additional 5 min
and then withdrawn at a rate of 0.5 mm per minute to prevent leakage. The
resulting wound was sutured with surgical nylon, and mice were inspected daily as
part of the postoperational care.
EAE induction. Mice were immunized subcutaneously in two sites (left and right
flanks) with 150 μg of PLP 139–151 (New England Peptide, Gardner, MA) peptide
that was emulsified in complete Freund’s adjuvant (CFA; Sigma-Aldrich) con-
taining 200 μg Mycobacterium tuberculosis (Difco), followed by 200 ng pertussis
toxin (PT; List Biological Laboratories) in 0.2 ml PBS by intraperitoneal (i.p.)
injections at the time of immunization and 48 h later. Control mice were immu-
nized with CFA, followed by PT injection. Mice were scored daily by an inde-
pendent blinded researcher as follows: 0, no clinical signs; 0.5, partial loss of tail
tone; 1, loss of tail tone; 1.5, poor righting ability; 2, hind-limb weakness; 3, hind-
limb paralysis; 4, quadriparesis; and 5, moribund. Mice found dead were assigned a
score 5 each day until the end of the experiment.
In vivo analysis of NSC differentiation and proliferation. For determination
oligodendrogenesis in vivo naive SJL mice were injected i.p. with BrdU (120 mg per
kg body weight per day, Sigma Aldrich)12,18. In brief, mice were pulsed for 6
consecutive days and subjected to stereotactic injection of recombinant Chi3l3
1 day after the last BrdU injection as described below. Mice were killed 6 days after
the stereotactic injection and CNS tissue was preserved and subjected to immu-
nohistochemical analysis. For determination of NSC proliferation, mice were
pulsed with BrdU (300 mg per kg body weight) 12 and 24 h after stereotactic
injection of recombinant Chi3l3 into naive mice. Mice were killed 24 h after the last
BrdU injection, CNS tissue was preserved and subjected to immunohistochemical
analysis. All treatments following stereotactical injection were performed by an
independent researcher in a blinded fashion.
Immunostaining. Mice were deeply anesthetized in a CO2 chamber or lethally
anesthetized with a mixture of ketamine (415 mg per kg; Actavis Germany) and
xylazine (9.7 mg/lg; Bayer Health Care Germany) and then transcardially perfused
with ice-cold PBS. Brains and spinal cord were removed and snap frozen in liquid
nitrogen or fixed with 4% parafformaldehyde (PFA) and cryopreserved in sucrose.
Tissues were then stored at −80 °C until further use. For immunohistochemical
analysis, tissues were cut into sections of 10 or 25 μm thickness in a cryostat and
subjected to further procedures. For immunocytochemical analysis, culture med-
ium was removed from adherent cells and subjected to further procedures.
For immunostaining, cells or tissues were fixed with 4% PFA for 10 min,
washed with PBS for 15 min, blocked with 8% horse serum, 3% BSA and 0.3%
Triton X-100 in PBS for 1 h and then incubated with primary antibodies at the
indicated concentrations at 4 °C overnight. Cells or sections were then rinsed and
incubated for 1 h with the appropriate Alexa Fluor 488, −594, or −647 secondary
antibodies (1:500, Molecular Probes). For nuclear staining, cells or sections were
incubated with TO-PRO-3 (1:1000; Life Technologies) or DAPI (1:10000; Sigma)
for 1 min, washed, and covered with coverslips. Negative control sections for each
animal/cell sample were treated identically, except that the primary antibodies were
omitted. Regions of interest were analyzed with a confocal microscope (LSM 510
Laser Scanning Microscope and LSM 3D analysis software, Linux, or an Operetta®
High Content Screening System and Columbus Image Analysis System, Perkin
Elmer).
For analysis of murine tissue and cells, primary antibodies at working
concentrations were: rat anti-BrdU (1:100; Accurate Chemical, cat#
YSRTMCA2060GA), rat anti-CD11b (1:50; BD Biosciences, cat# 550282), mouse
anti-CD45 (1:100, BioLegend, cat# 103101), rat anti-CD4 (1:200, BD Bioscience,
cat# 550278) rabbit anti Chi3l3 (1:50; Stemcell Technology, cat# 60130), rabbit
anti-Doublecortin (Dcx, 1:100; Abcam, cat# ab18723), mouse anti-GFAP (1:500;
BD Bioscience, cat# 610566), mouse anti-Ki76-FITC (1:100; BD Bioscience, cat#
617472), mouse anti-Map2 (1:250; Sigma-Aldrich, cat# M9942), rabbit anti-NG2
(1:100; Millipore, cat# ab5320), mouse anti-O4 (1:100; Millipore, cat# MAB345),
rabbit anti-p-Pyk2 (Tyr402; 1:500, CST, cat# 3291 S), rabbit anti-p-cRaf (Ser259;
1:500, CST, cat# 9421 P), rabbit anti-Sox2 (1:500, Thermo Fisher Scientific, cat#
A24339), rabbit anti-p-p38MAPK (THr180/Tyr182; 1:500, CST, cat#4511 P),
rabbit anti-p-PLCγ2 (Tyr1217; 1:500, CST, cat# 3871 P), rabbit anti-p-PI(3)K
(Tyr458; 1:500, CST cat# 4228 P), rabbit anti-p-Erk1/2 (Thr202/Tyr204; 1:500,
CST, cat# 9101), rabbit anti-p-EGFR (Tyr1068; 1:100, CST, cat# 3777).
For the analysis of human cells, primary antibodies at working concentrations
were: rat anti-MBP (1: 125, Millipore, cat# MAB386), goat anti-DCX (1:250,
SantaCruz, cat# sc-8066), goat anti-SOX2 (1: 250, R&D Systems, cat# AF2018),
goat anti-GFAP (1: 250, Santa Cruz, cat# sc-6170), rabbit anti-NG2 (1: 125,
Millipore, cat# AB5320). Secondary antibodies at working concentrations were:
Alexa Fluor 488 donkey anti-rat IgG (1:250, Thermofisher scientific, cat# A21208),
Alexa Fluor 488 donkey anti-rabbit IgG (1:250, Thermofisher scientific, cat#
A21206), Alexa Fluor 594 donkey anti-goat IgG (1:250, Thermofisher scientific,
cat# A11058).
Confocal and non-confocal fluorescence microscopy. For quantification of
in vivo stem cell differentiation and Chi3l3 expression analysis, regions of interest
around the lateral ventricle were analyzed with a LSM 510 Laser Scanning
microscope and LSM 3D analysis software. The periventricular area was defined as
the 200 µm adjacent to the ventricular lumen all around the lateral ventricles
including the entire width of the corpus callosum directly above the lateral ven-
tricles. Cells labeled with NG2 and/or BrdU were quantified using a × 63 water-
immersion objective18. The region of interest around the lateral ventricle labeled
with Chi3l3 and/or CD11b was imaged using × 20 objective or × 63 water-
immersion objective. Chi3l3 colocalization was analyzed and displayed as ortho-
view of a z-stack.
Non-confocal fluorescence analysis was performed using the Operetta® High
Content Screening System with a 20xWD or × 60 high NA objective and Columbus
Image Analysis System (Perkin Elmer). Mean fluorescence intensity for analysis of
phospho-protein staining intensity signal was calculated by automated
identification individual cells and subsequent automated mean staining intensity
calculation using a Columbus Image Analysis System (Perkin Elmer). A minimum
of 100 cells per condition was analyzed.
Hematoxilin and eosin stain analysis. Inflammatory lesions in brain and spinal
cord were assessed with hematoxylin and eosin staining. In the brain, lesions were
defined as accumulations of at least 20 mononuclear cells as previously described
by Rasmussen et al.12. Lesions were counted and their location mapped onto a
brain-diagram. Spinal cords were cut into eight segments and sectioned in order to
have eight sections representative of the entire spinal cord. The degree of
inflammation was determined by counting the number of quadrants that contained
inflammatory lesions for each of the eight segments65. Data were presented as the
percentage of total quadrants that contained inflammatory infiltrates.
Murine NSC isolation and culture. Embryonic day 14.5 (E14.5) NSCs were iso-
lated from cerebral cortices of timed C57BL/6 mouse embryos. Neural tissue was
digested with the Neural Tissue Dissociation Kit (P) (Miltenyi Biotec). The cell
suspension was cultured in NSC medium containing DMEM:F12 (Sigma Aldrich),
1% N2 supplement (Life Technologies), penicillin (50/ml), streptomycin (50 mg/
ml), and recombinant human fibroblast growth factor/recombinant human epi-
dermal growth factor (FGF/EGF; 20 ng/ml each, Miltenyi Biotec). For main-
tenance, fresh medium was added to the culture every 2–3 days and neurospheres
were dissociated and passaged before reaching a critical size with necrotic cores.
For analysis of Chi3l3-dependent proliferation, NSCs were plated at 1000 cells/
ml in proliferation medium containing DMEM:F12 (Sigma Aldrich), 2%
B27 supplement (Life Technologies), penicillin (50 U/ml), streptomycin (50 mg/
ml) and recombinant human fibroblast growth factor/recombinant human
epidermal growth factor (FGF/EGF; 20 ng/ml each, Miltenyi Biotec) in the
presence of 100 ng/ml recombinant Chi3l3 or PBS. Number of neurospheres per
well were analyzed after 1 week of culture.
Generation of signaling-deficient NSCs. E14.5 NSCs were infected with lenti-
virus stocks by spinoculation. For this, E14.5 NSCs spheres were disaggregated into
single cells, and resuspended in proliferation medium containing 8 µg/ml poly-
brene (Sigma). Virus stocks were added at 10 multiplicity of infection, and
cell–virus suspensions were centrifuged in ultra-low-adhesion round bottom 96-
well plates (Corning Costar #7007) at 800 rcf for 60 min. Cell/virus pellets were
incubated at 37 °C for 3 h, before they were resuspended in 2 ml medium and
transferred to a six-well dish. After 72 h, puromycin or zeocin were added at 0.2 µg/
ml and 25 µg/ml, respectively, to select for transfected cells. The rate of shRNA
knockdown or overexpression of GFP-constructs was analyzed by qRT-PCR of the
corresponding gene or flow cytometry, respectively. The fraction of GFP-
expressing cells was analyzed by flow cytometry. Cells were used for experiments
within five passages post transfection.
Murine NSC differentiation and proliferation in vitro. For analysis of Chi3l3-
dependent neural stem cell differentiation, NSCs were dissociated, washed and
plated at 5 × 105 cells per well on glass coverslips (12 mm diameter; Electron
Microscopy Sciences) precoated with laminin (10 μg/ml, Life Technologies) and
cultured in NSC differentiation medium containing DMEM:F12 (Sigma Aldrich),
2% B27 supplement (Life Technologies), penicillin (50 U/ml), streptomycin (50
mg/ml) in the presence of 0–1000 ng/ml recombinant Chi3l3, (R&D Systems Inc.).
For functional validation of Pyk2-, EGFR-dependent oligodendrogenesis, NSCs
were plated as described above and pretreated (45 min) with different concentra-
tions of the pharmacological inhibitor (Pyk2 inhibitor PF-431396, 1 μg/ml Sigma
Aldrich; EGFR inhibitor AZD9831, 200 nM, Biozol; Gefitinib, 1 μM, AstraZeneca;
U0126, 10 μM, (Sigma Aldrich) or heparin (1 μg/ml, Sigma Aldrich) followed by
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addition of 100–500 ng/ml Chi3l3, 100–500 ng/mg hChi3L1, 100–500 ng/mg
hChit1, 100 ng/ml EGF or PBS to the culture.
For analysis of cell death during Chi3l3-dependent neural stem cell
differentiation, single cells were seeded as described above. PI (5 μg/ml; Roth) was
added to the culture 10 min prior termination of the culture at 3 or 5 days. Cells
were immediately fixed and subjected to further immunocytochemical analysis. For
analysis of proliferation during Chi3l3-dependent neural stem cell differentiation,
cells were pulsed with BrdU (10 μM; Sigma Aldrich) prior termination of the
culture at 3 or 5 days of differentiation.
Human neural stem cell differentiation. For analysis of hCHI3L1- or hCHIT1-
dependent human neural stem cell differentiation, human NSCs (H9, N7800–100,
Thermofisher scientific) were dissociated, washed and plated at 5 × 105 cells on
glass coverslips (diameter: 18 mm, Thermofisher scientific) precoated with poly-L-
lysine (0.01% solution, Sigma) and cultured for 1 or 2 weeks in NSC differentiation
medium containing NeuroBasal media, 2% B27 supplement, Glutamax, and
antibiotic–antimycotic (Thermofisher scientific) in the presence of 250 ng/ml
recombinant human CHI3L1 and CHIT1 (all R&D Systems Inc.).
qRT-PCR. For quantitative real-time reverse transcription (qRT) PCR, cells or
tissues were lysed, and RNA was isolated using Trizol reagent (Life Technologies)
according to the manufacturer's manual. Total RNA samples were subjected to
complementary DNA (cDNA) generation using the Applied Biosystems high
capacity cDNA Reverse Transcription Kit. Samples were then subjected to real-
time PCR analysis on an ABI 7500 System (Applied Biosystems). Genes analyzed
were detected using commercially available assays from Applied Biosystems: Ccnd1
(Mm0043258_g1), Ccnd2 (Mm00438070_m1), Chi3l3 (Mm00657889_mH), Cspg4
(Mm00507256_m1), Gapdh (Mm00484668_m1), Hes5 (Mm00439311_g1), Hprt
(Mm03024075_m1), Id2 (Mm01293217_g1), Id4 (Mm00499701_m1), Map2
(Mm00485230_m1), Olig1 (Mm00497537_s1), Olig2 (Mm01210556_m1), Ptk2b
(Mm00552827_m1), Sox10 (Mm01300162_m1) or primers and probes from
Eurofin MWG Operon for 18 s (forward: TTCGAACGTCTGCCCTATCAA;
reverse: TCCCCGTCACCCATGGT; probe: CGATGGTAGTCGCCGTGCCTAC
CA) and GFAP (forward: TTTCTCCAACCTCCAGATCC; reverse: CCGCATC
TCCACAGTCTTTA; probe: FAM-CCAGCCTGGACACCAAATCCG-TAM).
Relative mRNA level was normalized against the housekeeping genes Gapdh, 18 s
or Hprt.
Statistical analysis. Samples size for each experiment was chosen based on pre-
vious experiments. Samples were allocated into experimental groups at the start of
each individual experiment. The in vitro experiments were not randomized. For
in vivo experiments, mice were randomly subjected to each group. No data were
excluded. The investigators were blinded as to experimental groups during data
collection and analysis. Specifically, for in vivo experiments, EAE scoring, and
subsequent tissue analysis was performed by an independent researcher, who was
blinded to experimental treatment groups.
Prism software (Graph Pad Software) was used for statistical analysis. All error
bars shown represent SEM. The following number of replicates were used: For
Fig. 3 data are representative of three independent experiments with the following
number of replicates: (A,B) n= 2; (C) pPyk 5 min n= 80 (Control) and n= 150
(Chi3l3), 15 min n= 100 (Control) and n= 103 (Chi3l3), 30 min n= 43 (Control)
and n= 69 (Chi3l3); p-cRaf 5 min n= 100 (Control, Chi3l3), 15 min n= 99
(Control) and n= 101 (Chi3l3), 30 min n= 97 (Control) and n= 100 (Chi3l3);
p38MAPK 5min n= 72 (Control) and n= 105 (Chi3l3), 15 min n= 103 (Control)
and n= 102 (Chi3l3), 30 min n= 78 (Control) and n= 98 (Chi3l3); p-PLCγ2 5
min n= 99 (Control) and n= 100 (Chi3l3), 15 min n= 102 (Control) and n= 101
(Chi3l3), 30 min n= 99 (Control) and n= 100 (Chi3l3); p-PI(3)K 5min n= 99
(Control) and n= 104 (Chi3l3), 15 min n= 101 (Control) and n= 105 (Chi3l3),
30 min n= 88 (Control) and n= 47 (Chi3l3); pERK1/2 5 min n= 101 (Control)
and n= 119 (Chi3l3), 15 min n= 102 (Control) and n= 107 (Chi3l3), 30 min n=
100 (Control) and n= 118 (Chi3l3); (E) n= 3 replicates; (F) n= 2 replicates (−)
and n= 3 replicates (+ ); (G) n= 3 replicates; (I) n= 18 (−/−), n= 8 (−/+ )
replicates), n= 12 (+ /−;+ /+ ); (J) n= 3 replicates; (H) data are representative
of two independent experiments with n= 3 replicates); For Fig. 4 data are
representative of three independent experiments with the following number of
replicates: (B) n= 93 (PBS), n= 98 (Chi3l3) and n= 108 (EGF); (C left) n= 9
(−/−), n= 7 (+ /−), and n= 6 (+ /+ ); (C right) n= 8 (−/−), n= 17 (+ /−),
and n= 9 (+ /+ ); (D) n= 3 (−/+ /−), n= 3 (+ /+ /−), n= 3 (−/−/+ ), and
n= 3 (+ /−/+ ); (E) n= 402 (−/−/−), n= 1006 (+ /−/−), n= 648 (+ /−/+ ),
n= 421 (−/+ /−) and n= 1324 (−/+ /−) individual cells; (F) n= 302
(−/−/+ /−), n= 704 (+ /−/+ /−), n= 450 (+ /−/−/+ ), n= 637 (−/+ /
+ /−) and n= 497 (−/+ /−/+ ) individual cells; In Fig. 7b linear regression
analysis was performed to determine whether the differences between the groups
are significant. Significant differences were assumed at the 5% level and presented
as p values (p < 0.05).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
The data that support the findings of this study are available from the corre-
sponding author upon reasonable request. A Reporting Summary for this Article is
available as a Supplementary Information file.
Received: 1 November 2017 Accepted: 18 December 2018
References
1. McTigue, D. M. & Tripathi, R. B. The life, death, and replacement of
oligodendrocytes in the adult CNS. J. Neurochem. 107, 1–19 (2008).
2. Butovsky, O. et al. Microglia activated by IL-4 and IFN-g differentially induce
neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol.
Cell Neurosci. 31, 149–160 (2006).
3. Mahad, D. H., Trapp, B. D. & Lassmann, H. Pathological mechanisms in
progressive multiple sclerosis. Lancet Neurol. 14, 183–193 (2015).
4. Miron, V. E. et al. M2 microglia and macrophages drive oligodendrocyte
differentiation during CNS remyelination. Nat. Neurosci. 16, 1211–1218
(2013).
5. Xing, Y. L. et al. Adult neural precursor cells from the subventricular zone
contribute significantly to oligodendrocyte regeneration and remyelination. J.
Neurosci. 34, 14128–14146 (2014).
6. Capilla-Gonzalez, V. et al. The iation. Stem Cells 32, 59–69 (2014).
7. Alvarez-Buylla, A. & Lim, D. A. For the long run: maintaining germinal niches
in the adult brain. Neuron 41, 683–686 (2004).
8. Pluchino, S. et al. Persistent inflammation alters the function of the
endogenous brain stem cell compartment. Brain 131, 2564–2578 (2008).
9. Starossom, S. C., Imitola, J., Wang, Y., Cao, L. & Khoury, S. J. Subventricular
zone microglia transcriptional networks. Brain Behav. Immun. 25, 999 (2010).
10. Miron, V. E. & Franklin, R. J. M. Macrophages and CNS remyelination. J.
Neurochem. 130, 165–171 (2014).
11. Miron, V. E., Kuhlmann, T. & Antel, J. P. Cells of the oligodendroglial lineage,
myelination, and remyelination. Biochim. Biophys. Acta 1812, 184–193 (2011).
12. Rasmussen, S. et al. Persistent activation of microglia is associated with
neuronal dysfunction of callosal projecting pathways and multiple sclerosis-
like lesions in relapsing--remitting experimental autoimmune
encephalomyelitis. Brain 130, 2816–2829 (2007).
13. Ruckh, J. M. et al. Rejuvenation of regeneration in the aging central nervous
system. Cell Stem Cell 10, 96–103 (2012).
14. Najm, F. J. et al. Drug-based modulation of endogenous stem cells promotes
functional remyelination in vivo. Nature 522, 216–220 (2015).
15. Piao, J. et al. Human embryonic stem cell-derived oligodendrocyte progenitors
remyelinate the brain and rescue behavioral deficits following radiation. Cell
Stem Cell 16, 470–482 (2010).
16. Franklin, R. J. M. Regenerative medicines for remyelination: from aspiration
to reality. Cell Stem Cell 16, 576–577 (2015).
17. Butovsky, O. et al. Induction and blockage of oligodendrogenesis by
differently activated microglia in an animal model of multiple sclerosis. J. Clin.
Invest. 116, 905–915 (2006).
18. Rasmussen, S. et al. Reversible neural stem cell niche dysfunction in a model
of multiple sclerosis. Ann. Neurol. 69, 878–891 (2011).
19. Ponomarev, E. D., Maresz, K., Tan, Y. & Dittel, B. N. CNS-derived
interleukin-4 is essential for the regulation of autoimmune inflammation and
induces a state of alternative activation in microglial cells. J. Neurosci. 27,
10714–10721 (2007).
20. Bussink, A. P., Speijer, D., Aerts, J. M. F. G. & Boot, R. G. Evolution of
mammalian chitinase(-like) members of family 18 glycosyl hydrolases.
Genetics 177, 959–970 (2007).
21. Osborne, L. C. et al. Coinfection. Virus-helminth coinfection reveals a
microbiota-independent mechanism of immunomodulation. Science 345,
578–582 (2014).
22. Sutherland, T. E. et al. Chitinase-like proteins promote IL-17-mediated
neutrophilia in a tradeoff between nematode killing and host damage. Nat.
Immunol. 15, 1116–1125 (2014).
23. Arora, M. et al. Simvastatin promotes Th2-type responses through the
induction of the chitinase family member Ym1 in dendritic cells. Proc. . Natl.
Acad. Sci. USA 103, 7777–7782 (2006).
24. Pepe, G., Calderazzi, G., De Maglie, M., Villa, A. M. & Vegeto, E.
Heterogeneous induction of microglia M2a phenotype by central
administration of interleukin-4. J. Neuroinflamm. 11, 775–14 (2014).
25. Correale, J. & Farez, M. Association between parasite infection and immune
responses in multiple sclerosis. Ann. Neurol. 61, 97–108 (2007).
26. Farez, M. F. et al. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1
promote central nervous system neuroinflammation in progressive EAE. Nat.
Immunol. 10, 958–964 (2009).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08140-7 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:217 | https://doi.org/10.1038/s41467-018-08140-7 | www.nature.com/naturecommunications 13
27. Chan, S. M., Ermann, J., Su, L., Fathman, C. G. & Utz, P. J. Protein
microarrays for multiplex analysis of signal transduction pathways. Nat. Med.
10, 1390–1396 (2004).
28. Buckbinder, L. et al. Proline-rich tyrosine kinase 2 regulates osteoprogenitor
cells and bone formation, and offers an anabolic treatment approach for
osteoporosis. Proc. Natl. Acad. Sci. USA 104, 10619–10624 (2007).
29. Aguirre, A. & Gallo, V. Reduced EGFR signaling in progenitor cells of the
adult subventricular zone attenuates oligodendrogenesis after demyelination.
Neuron Glia Biol. 3, 209–220 (2008).
30. Aguirre, A., Dupree, J. L., Mangin, J. M. & Gallo, V. A functional role for
EGFR signaling in myelination and remyelination. Nat. Neurosci. 10, 990
(2007).
31. Aguirre, A., Rubio, M. E. & Gallo, V. Notch and EGFR pathway interaction
regulates neural stem cell number and self-renewal. Nature 467, 323–327 (2010).
32. Nicolay, D. J., Doucette, J. R. & Nazarali, A. J. Transcriptional control of
oligodendrogenesis. Glia 55, 1287–1299 (2007).
33. Franklin, R. J. M. & Ffrench-Constant, C. Remyelination in the CNS: from
biology to therapy. Nat. Rev. Neurosci. 9, 839–855 (2008).
34. Yu, Y. et al. Olig2 targets chromatin remodelers to enhancers to initiate
oligodendrocyte differentiation. Cell 152, 248–261 (2013).
35. Hu, Q. et al. The Egfr-Sox2-Egfr feed-back loop positively regulates the self-
renewal of neural precursor cells. Stem Cells 28, 279–86 (2009).
36. Bonneh-Barkay, D., Wang, G., LaFramboise, W. A., Wiley, C. A. & Bissel, S. J.
Exacerbation of experimental autoimmune encephalomyelitis in the absence
of breast regression protein 39/chitinase 3-like 1. J. Neuropathol. Exp. Neurol.
71, 948–958 (2012).
37. Correale, J. & Fiol, M. Chitinase effects on immune cell response in
neuromyelitis optica and multiple sclerosis. Mult. Scler. 17, 521-31 (2010).
38. Novakova, L. et al. Cerebrospinal fluid biomarkers as a measure of disease
activity and treatment efficacy in relapsing-remitting multiple sclerosis. J.
Neurochem. 141, 296–304 (2016).
39. Ding, X. et al. Silencing IFN-γ binding/signaling in astrocytes versus microglia
leads to opposite effects on central nervous system autoimmunity. J. Immunol.
194, 4251–4264 (2015).
40. Mayo, L. et al. Regulation of astrocyte activation by glycolipids drives chronic
CNS inflammation. Nat. Med. 20,1147–1156 (2014).
41. Modvig, S. et al. Relationship between cerebrospinal fluid biomarkers for
inflammation, demyelination and neurodegeneration in acute optic neuritis.
PLoS. ONE 8, e77163 (2013).
42. Møllgaard, M., Degn, M., Sellebjerg, F., Frederiksen, J. L. & Modvig, S.
Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic
biomarkers in early multiple sclerosis. Eur. J. Neurol. 23, 898–905 (2016).
43. Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M. & Rossi, F. M. V.
Infiltrating monocytes trigger EAE progression, but do not contribute to the
resident microglia pool. Nat. Neurosci. 14,1142–1149 (2011).
44. Wuerfel, J. et al. Mouse model mimics multiple sclerosis in the clinico-
radiological paradox. Eur. J. Neurosci. 26, 190–198 (2007).
45. Olah, M. et al. Identification of a microglia phenotype supportive of
remyelination. Glia 60, 306–321 (2011).
46. Verma, N. et al. PYK2 sustains endosomal-derived receptor signalling and
enhances epithelial-to-mesenchymal transition. Nat. Commun. 6, 6064 (2015).
47. Rolón-Reyes, K. et al. Microglia activate migration of glioma cells through a
Pyk2 intracellular pathway. PLoS. ONE 10, e0131059 (2015).
48. Galvez-Contreras, A. Y., Quiñones-Hinojosa, A. & Gonzalez-Perez, O. The
role of EGFR and ErbB family related proteins in the oligodendrocyte
specification in germinal niches of the adult mammalian brain. Front. Cell.
Neurosci. 7, 258 (2013).
49. Oyagi, A. & Hara, H. Essential roles of heparin-binding epidermal growth
factor-like growth factor in the brain. CNS Neurosci. Ther. 18, 803–810 (2012).
50. Gonzalez-Perez, O. & Alvarez-Buylla, A. Oligodendrogenesis in the
subventricular zone and the role of epidermal growth factor. Brain. Res. Rev.
67, 147–156 (2011).
51. Amir-Levy, Y., Mausner-Fainberg, K. & Karni, A. Treatment with anti-EGF Ab
ameliorates experimental autoimmune encephalomyelitis via induction of
neurogenesis and oligodendrogenesis. Mult. Scler. Int. 2014, 926134 (2014).
52. Gonzalez-Perez, O. & Quiñones-Hinojosa, A. Dose-dependent effect of EGF
on migration and differentiation of adult subventricular zone astrocytes. Glia
58, 975–983 (2010).
53. Fernandes, H., Cohen, S. & Bishayee, S. Glycosylation-induced conformational
modification positively regulates receptor-receptor association: a study with an
aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed
in cancer cells. J. Biol. Chem. 276, 5375–5383 (2001).
54. Azimzadeh Irani, M., Kannan, S. & Verma, C. Role of N-glycosylation in
EGFR ectodomain ligand binding. Proteins 85, 1529–1549 (2017).
55. Sun, Y. J. et al. The crystal structure of a novel mammalian lectin, Ym1,
suggests a saccharide binding site. J. Biol. Chem. 276, 17507–17514 (2001).
56. Chang, N. C. et al. A macrophage protein, Ym1, transiently expressed during
inflammation is a novel mammalian lectin. J. Biol. Chem. 276, 17497–17506
(2001).
57. Sellebjerg, F. et al. Increased cerebrospinal fluid concentrations of the
chemokine CXCL13 in active MS. Neurology 73, 2003–2010 (2009).
58. Burman, J. et al. YKL-40 is a CSF biomarker of intrathecal inflammation in
secondary progressive multiple sclerosis. J. Neuroimmunol. 292, 52–57 (2016).
59. Comabella, M. et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated
with conversion to multiple sclerosis. Brain 133, 1082 (2010).
60. Zhang, J. & Jiao, J. molecular biomarkers for embryonic and adult neural stem
cell and neurogenesis. BioMed Res. Int. 2015, 1–14 (2015).
61. Oikari, L. E. et al. Cell surface heparan sulfate proteoglycans as novel markers
of human neural stem cell fate determination. Stem Cell Res. 16, 92–104
(2016).
62. Yan, Y. et al. Efficient and rapid derivation of primitive neural stem cells and
generation of brain subtype neurons from human pluripotent stem cells. Stem
Cells Transl. Med. 2, 862–870 (2013).
63. Obernier, K., Tong, C. K. & Alvarez-Buylla, A. Restricted nature of adult
neural stem cells: re-evaluation of their potential for brain repair. Front.
Neurosci. 8, 162 (2014).
64. Robinson, M. J. et al. Mutation of position 52 in ERK2 reates a nonproductive
binding mode for adenosine 5‘-triphosphate †,‡. Biochemistry 35, 5641–5646
(1996).
65. Millward, J. M., Lobner, M., Wheeler, R. D. & Owens, T. Inflammation in the
central nervous system and Th17 responses are inhibited by IFN- induced IL-
18 binding protein. J. Immunol. 185, 2458–2466 (2010).
Acknowledgements
We thank N. Asselborn for technical assistance, and S.U. Schmitz and H. Schroll for
helpful discussions. This study was supported by grants from the NIH (R01 AI043496 to
S.J.K.), the German Research Council (DFG Exc 257 to F.P. and DFG STA 1586/1–1 to S.
C.S), and an Oppenheim research prize (2016 by Novartis) and Charité research scho-
larships to S.C.S. We also acknowledge support from the Open Access Publication Fund
of Charité - Universitätsmedizin Berlin.
Author contributions
S.C.S and S.J.K. planned the study and wrote the manuscript. S.C.S., M.O., L.C., A.Y., F.
Q., C.I.D., F.P., J.I., M.M. planned experiments. S.C.S., T.W., J.C.G., S. R-S., F.W., M.O., J.
J.T, L.C., A.Y., J.I., M.M., C.I.D. performed and interpreted experiments. D.S. provided
methodological expertize. All authors discussed the results and conclusions and reviewed
the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-08140-7.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08140-7
14 NATURE COMMUNICATIONS |          (2019) 10:217 | https://doi.org/10.1038/s41467-018-08140-7 | www.nature.com/naturecommunications
